Tyruko (natalizumab) was launched in the US in November 2025 as the first and only multiple-sclerosis biosimilar, approved for all indications of the reference medicine
The coverage policies and prior authorization requirements described here apply to Anthem-administered plans broadly, but if your card says Blue Cross Blue Shield specifically, the policies may differ depending on which BCBS licensee administers your plan
(2000) Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein
O uso da semaglutida oral para o tratamento da obesidade foi avaliada no estudo clnico OASIS 1 (Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in Subjects With Overweight or Obesity), o qual demonstrou eficcia na dose de 50mg diria prxima a da semalgutida subcutnea na dose de 2,4mg semanal, porm seu uso ainda no est aprovado em bula para pacientes no diabticos
These injections compliment the medication to help the body produce energy as well as to improve blood sugar levels
Overall, Adderall and Vyvanse are both effective at treating ADHD in children and adults and are generally well-tolerated, even up to daily doses of 70 mg
